A PHASE Ib/II, OPEN LABEL, MULTICENTER, RANDOMIZED UMBRELLA STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE IMMUNOTHERAPY-BASED TREATMENT COMBINATIONS IN PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE OR METASTATIC GASTRIC OR GASTROESOPHAGEAL JUNCTION CANCER (MORPHEUS-GASTRIC CANCER)
Study of Treatment Combinations in Patients with Gastric or Gastroesophageal Junction Cancer (Morpheus-Gastric Cancer)
Sponsor: F. Hoffmann- La Roche Ltd.
Enrolling: Male and Female Patients
IRB Number: AAAR4882
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: This study will evaluate the efficacy, safety, and pharmacokinetics of immunotherapy-based treatment combinations in patients with gastric or gastroesophageal junction cancer. To evaluate the efficacy of immunotherapy-based treatment combinations in all arms during Stage 1 and stage 2.
This study is closed
Investigator
Gulam Manji, MD, PhD
Do You Qualify?
Are you 18 years or older? Yes No
Have you been diagnosed with adenocarcinoma of gastric or gastroesophageal junction? Yes No
Are you able to walk, care for yourself, and do light physical activities like light housework or office work? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE